摘要
目的观察度洛西汀与艾司西酞普兰治疗女性抑郁症的疗效及安全性。方法67例女性首发抑郁症患者随机分为度洛西汀组(34例)和艾司西酞普兰组(33例),治疗剂量分别为40～60mg/d和10～15mg/d,观察8周。用汉密尔顿抑郁量表(HAMD17)评定疗效,用不良反应量表(TESS)评估不良反应和安全性。结果度洛西汀组有32例完成8周的观察,艾司西酞普兰组有31例。至第8周末度洛西汀组和艾司西酞普兰组的有效率分别为81.13%(26/32)、80.65%(25/31),差异无统计学意义(χ2=0.001,P=0.951),临床痊愈率分别为59.37%(19/32)、54.84%(17/31),差异无统计学意义(χ2=0.132,P=0.716)。治疗第1周末,度洛西汀组起效率为37.50%(12/32),与艾司西酞普兰组的41.93%(13/31)比差异无统计学意义(χ2=0.129,P=0.719)。度洛西汀组发生比例大于10%的不良反应为便秘、失眠和食欲降低,艾司西酞普兰组为失眠和疲劳。结论度洛西汀和艾司西酞普兰对女性抑郁症患者同样安全有效。
Objective： To observe the efficacy and safety of duloxetine and escitalopram in female patients with depressive disorder. Methods： Sixty - seven patients with first - episode depression were randomly divided into duloxetine group （n =34） and escitalopram group （n = 33 ） . The patients were treated with duloxetine （40 - 60mg/d） or escitalopram （ 10- 15mg/d ） for 8 weeks. The efficacy was assessed with Hamilton depression rating scale （HAMD 17 ） and the side effects were assessed with treatment emergent symptoms scale （TESS）. Results： Thirty - two patients in duloxetine group and 31 patients in escitalopram group completed the 8 weeks＇ study. After the 8 - weeks treatment, the response rates in duloxetine group and escitalopram group were 81.13% and 80.65% respectivly,without significant difference（Χ^2 =0. 001 ,P =0.951 ）. The clinical recovery rate was 59.37% in duloxetine group and 54. 84% in escitalopram group , with no difference （Χ^2 = 0. 132, P = 0. 716 ）. After the first week of treatment, the response rate was 37.50% in duloxetine group and 41.93 % in escitalopram group without difference （Χ^2 = 0. 129, P = 0.719 ）. The frequent reported adverse effects above 10% were constipation, insomnia,inappetence in duloxetine group and insomnia, fatigue in escitalopram group. Conclusion： Duloxetine and escitalopram are both effective and safe in female patients with depressive disorder.
出处
《上海精神医学》
2009年第3期166-168,共3页
Shanghai Archives of Psychiatry
